What You Should Know:
– PreciseDx®, a leader in AI-powered diagnostics for oncology, announces a crucial collaboration with UCLA’s Department of Pathology and Laboratory Medicine.
– The research initiative focuses on evaluating PreciseDx’s innovative tool, PreciseBreast™, for its ability to accurately assess the risk of recurrence in patients diagnosed with triple-negative breast cancer (TNBC).
Why Focus on Triple-Negative Breast Cancer?
- TNBC Challenges: Accounting for only 10-20% of breast cancer cases, TNBC is particularly aggressive and carries a higher risk of recurrence. It is often linked to younger women, BRCA1/2 gene mutations, and ethnic/racial disparities. Traditional treatments offer limited effectiveness.
- Need for Advanced Tools: Recent discoveries of TNBC subtypes and the potential of immunotherapy highlight the urgent need for more sophisticated tools for TNBC categorization and risk assessment. This is crucial for developing personalized treatment plans and improving patient outcomes.
Building on Previous Success
This new study expands upon a prior subgroup analysis of TNBC patients from the PreciseBreast-Mount Sinai Hospital validation study. UCLA’s involvement allows for the evaluation of a larger, well-annotated TNBC cohort from the UCLA Health System.
The Power of AI and Collaboration
The collaborative study integrates cutting-edge AI algorithms with comprehensive clinical data. The goal is to validate PreciseBreast™ as a reliable digital breast cancer assay for:
- Enhanced Early Detection: PreciseBreast™ aims to identify TNBC recurrence at an earlier stage, allowing for timely intervention.
- Personalized Treatment Strategies: This AI-powered tool can potentially support the development of individualized treatment plans based on each patient’s specific needs.
